Vantage logo

Who will buy Qiagen?

The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.

Vantage logo

Oncocyte banks on a new kind of liquid biopsy

The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…

Vantage logo

Illumina bets on Pacific, not nanopores

Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.